

Development of a Macrophage Activation Based Therapeutic Candidate for Metabolic Dysfunction Associated Steatohepatitis (MASH) and Liver Fibrosis



METABOLIC	Candidate
Product Type	Gene & Nucleic acids
Indication	MASH & Liver Fibrosis
Target	Let-7i-5p microRNA
MoA(Mechanism of Action)	NRT-FX_01 inhibits let-7i-5p to restore TSP1 expression, thereby modulating the CD47-SIRPα macrophage immune checkpoint. This promoting macrophage-mediated clearance of necroptotic hepatocytes and helps attenuate MASH and liver fibrosis.
Competitiveness	• Indication: Patients with MASH-associated liver fibrosis who require disease-modifying treatment due to limited response to lifestyle intervention or existing pharmacologic therapies. • NRT-FX_01 is a first-in-class RNA therapeutic for MASH-associated liver fibrosis that modulates macrophage activity through a fundamental, disease-modifying mechanism. • Excellent safety profile demonstrated in toxicity studies.
Development Stage	Candidate
Route of Administration	Intravenous (IV) Administration

Any unauthorized distribution or reproduction of this material is strictly prohibited.